Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
39 results
D1.257 - Hereditary Angioedema in Bulgaria (1972-2025): A Longitudinal Comparative Study of Trends in Diagnosis, Mortality, and the Impact of Modern Therapies
D1.259 - Icatibant Use During Pregnancy: A South African Case Series
D1.261 - Phenotypic and Immunological Profiles of Chronic Urticaria: A Cross- Sectional Study From South India
D1.250 - Real-World Effectiveness and Safety of Icatibant for Hereditary Angioedema in China: An Interim Analysis of the EASTERN Study
D1.251 - High Cost of Stigma: Anticipated Workplace Stigma Drives Absenteeism while Healthcare Stigma Provokes Anxiety in HAE
D1.253 - Probiotic Co-administration to Improve Gastrointestinal Tolerability of Berotralstat in Hereditary Angioedema: a multicenter case series from the ITACA network
D1.254 - Comparison Between Classical and Updated Classifications in Patients Diagnosed with Isolated Angioedema: Finally, Did We Find the Ideal One?
D1.255 - Is it Angioedema? Unmasking a complete Melkersson-Rosenthal Syndrome
D1.256 - Chronic Inducible Urticaria in Real Life: A Single-Centre Retrospective Cohort
D1.258 - First real-life experiences with Sebetralstat as oral on-demand treatment for acute HAE attacks documented in a global angioedema disease registry
D1.260 - Clinical Characteristics and Hospitalization Patterns in Chronic Spontaneous Urticaria Patients in Bulgaria
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download